The transaction is expected to close in the second half of the year, making Silk Road a wholly owned subsidiary of Boston Scientific, according to a June 19 press release.
Silk Road Medical is known for its transcarotid artery revascularization devices and has completed over 85,000 procedures to date.
The TCAR system is a minimally invasive procedure that treats carotid artery disease by temporarily reversing blood flow to prevent plaque fragments from reaching the brain.
Silk Road has a market capitalization of about $854.7 million and saw a 28% revenue increase from 2022 to 2023, according to the release.